NBW Capital LLC grew its stake in SPDR S&P Biotech (NYSEARCA:XBI) by 68.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,875 shares of the exchange traded fund’s stock after buying an additional 33,534 shares during the quarter. SPDR S&P Biotech makes up 1.9% of NBW Capital LLC’s portfolio, making the stock its 28th biggest holding. NBW Capital LLC owned 0.16% of SPDR S&P Biotech worth $7,034,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Valeo Financial Advisors LLC bought a new position in shares of SPDR S&P Biotech in the fourth quarter worth about $102,000. Captrust Financial Advisors boosted its stake in shares of SPDR S&P Biotech by 126.2% in the third quarter. Captrust Financial Advisors now owns 1,192 shares of the exchange traded fund’s stock worth $103,000 after acquiring an additional 665 shares during the period. SeaCrest Wealth Management LLC bought a new position in shares of SPDR S&P Biotech in the fourth quarter worth about $146,000. Calton & Associates Inc. bought a new position in shares of SPDR S&P Biotech in the fourth quarter worth about $158,000. Finally, First Allied Advisory Services Inc. bought a new position in SPDR S&P Biotech during the fourth quarter valued at approximately $195,000.
SPDR S&P Biotech (NYSEARCA XBI) opened at $96.45 on Monday. SPDR S&P Biotech has a one year low of $66.00 and a one year high of $97.98. The company has a market capitalization of $5,300.00 and a P/E ratio of 5.29.
ILLEGAL ACTIVITY WARNING: “NBW Capital LLC Has $7.03 Million Holdings in SPDR S&P Biotech (XBI)” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/12/nbw-capital-llc-has-7-03-million-holdings-in-spdr-sp-biotech-xbi.html.
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.